Literature DB >> 11685117

Protease-activated receptor 1 and plasminogen activator inhibitor 1 expression in chronic allograft nephropathy: the role of coagulation and fibrinolysis in renal graft fibrosis.

G Grandaliano1, S Di Paolo, R Monno, G Stallone, E Ranieri, P Pontrelli, L Gesualdo, F P Schena.   

Abstract

BACKGROUND: Chronic allograft nephropathy (CAN), the major cause of renal graft failure, frequently displays extensive interstitial fibrin deposition. Little is known in regard to the cause of the altered coagulation/fibrinolysis balance and its relevance in the pathogenesis of CAN. Thrombin, present within the fibrin clots, can interact with a specific receptor, protease-activated receptor 1 (PAR-1), and modulate a variety of cell functions. On the other hand, the derangement of the fibrinolytic system may directly affect extracellular matrix (ECM) degradation.
METHODS: In the present study, we investigated, by in situ hybridization, PAR-1 gene expression and the mRNA levels for tissue factor and plasminogen activator inhibitor 1 (PAI-1), two key regulatory molecules of coagulation and fibrinolysis, in 16 CAN biopsies and in 10 normal human kidney grafts. The thrombin-induced transforming growth factor beta (TGF-beta) gene and protein expression in proximal tubular cells (PTC) was investigated by Northern blotting and ELISA, respectively.
RESULTS: Fibrin deposits, absent in normal grafts, were observed in the interstitial space and arterial wall of CAN. Tissue factor gene expression was not increased either at the vascular or at the interstitial level in CAN. On the contrary, PAI-1 gene expression, barely detectable in control tissue, was strikingly increased in CAN, with a distribution resembling the pattern of fibrin deposition. Note that PAI-1 gene expression was directly correlated with the degree of interstitial fibrosis. In addition, fibrin deposits were strictly associated with a marked increase of PAR-1 gene expression in endothelial cells and PTC. The tubular expression of PAR-1 was significantly higher in Banff grade II-III than in grade I. In vitro, incubation of PTC with thrombin caused a significant up-regulation of TGF-beta gene expression, followed by an increased TGF-beta release into the supernatant. Interestingly, urine from CAN patients contained significantly higher levels of TGF-beta.
CONCLUSIONS: Fibrin deposits in CAN may result from the increased expression of PAI-1 and the subsequent inhibition of fibrinolysis. The reduced fibrinolysis may cause, in turn, a decreased ECM turnover. Finally, thrombin, preserved in the active form within the fibrin clots, may interact with PAR-1 highly expressed on PTC and induce an up-regulation of ECM deposition in a TGF-beta-dependent manner.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11685117     DOI: 10.1097/00007890-200110270-00018

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  14 in total

1.  Thrombin down-regulates the TGF-beta-mediated synthesis of collagen and fibronectin by human proximal tubule epithelial cells through the EPCR-dependent activation of PAR-1.

Authors:  Jong-Sup Bae; In-San Kim; Alireza R Rezaie
Journal:  J Cell Physiol       Date:  2010-10       Impact factor: 6.384

2.  Anti-thrombin therapy during warm ischemia and cold preservation prevents chronic kidney graft fibrosis in a DCD model.

Authors:  F Favreau; R Thuillier; J Cau; S Milin; E Manguy; G Mauco; X Zhu; L O Lerman; T Hauet
Journal:  Am J Transplant       Date:  2009-12-02       Impact factor: 8.086

3.  Lysophosphatidic acid increases proximal tubule cell secretion of profibrotic cytokines PDGF-B and CTGF through LPA2- and Gαq-mediated Rho and αvβ6 integrin-dependent activation of TGF-β.

Authors:  Hui Geng; Rongpei Lan; Prajjal K Singha; Annette Gilchrist; Paul H Weinreb; Shelia M Violette; Joel M Weinberg; Pothana Saikumar; Manjeri A Venkatachalam
Journal:  Am J Pathol       Date:  2012-08-10       Impact factor: 4.307

Review 4.  The emerging role of coagulation proteases in kidney disease.

Authors:  Thati Madhusudhan; Bryce A Kerlin; Berend Isermann
Journal:  Nat Rev Nephrol       Date:  2015-11-23       Impact factor: 28.314

5.  Noninvasive prognostication of polyomavirus BK virus-associated nephropathy.

Authors:  Darshana Dadhania; Catherine Snopkowski; Thangamani Muthukumar; John Lee; Ruchuang Ding; Vijay K Sharma; Paul Christos; Heejung Bang; Sandip Kapur; Surya V Seshan; Manikkam Suthanthiran
Journal:  Transplantation       Date:  2013-07-27       Impact factor: 4.939

Review 6.  Oxidative stress, plasminogen activator inhibitor 1, and lung fibrosis.

Authors:  Rui-Ming Liu
Journal:  Antioxid Redox Signal       Date:  2008-02       Impact factor: 8.401

7.  Pulmonary epithelium is a prominent source of proteinase-activated receptor-1-inducible CCL2 in pulmonary fibrosis.

Authors:  Paul F Mercer; Robin H Johns; Chris J Scotton; Malvina A Krupiczojc; Melanie Königshoff; David C J Howell; Robin J McAnulty; Anuk Das; Andrew J Thorley; Terry D Tetley; Oliver Eickelberg; Rachel C Chambers
Journal:  Am J Respir Crit Care Med       Date:  2008-12-05       Impact factor: 21.405

Review 8.  Angiotensin II and progressive renal insufficiency.

Authors:  Jens Gaedeke; Nancy A Noble; Wayne A Border
Journal:  Curr Hypertens Rep       Date:  2002-10       Impact factor: 5.369

9.  Thrombin stimulates synthesis of macrophage colony-stimulating factor, granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor by human proximal tubular epithelial cells in culture.

Authors:  Yuko Shimaya; Michiko Shimada; Yoshiko Shutto; Takeshi Fujita; Reiichi Murakami; Norio Nakamura; Hideaki Yamabe; Ken Okumura
Journal:  Nephron Extra       Date:  2012-01-25

10.  Role of warm ischemia on innate and adaptive responses in a preclinical renal auto-transplanted porcine model.

Authors:  Ludivine Rossard; Frédéric Favreau; Sebastien Giraud; Raphael Thuillier; Sylvain Le Pape; Jean Michel Goujon; Alexandre Valagier; Thierry Hauet
Journal:  J Transl Med       Date:  2013-05-24       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.